[go: up one dir, main page]

PE20080100A1 - ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA - Google Patents

ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA

Info

Publication number
PE20080100A1
PE20080100A1 PE2007000634A PE2007000634A PE20080100A1 PE 20080100 A1 PE20080100 A1 PE 20080100A1 PE 2007000634 A PE2007000634 A PE 2007000634A PE 2007000634 A PE2007000634 A PE 2007000634A PE 20080100 A1 PE20080100 A1 PE 20080100A1
Authority
PE
Peru
Prior art keywords
seq
integrin
humanized
human
function
Prior art date
Application number
PE2007000634A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopf
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Pettit-Frere
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20080100A1 publication Critical patent/PE20080100A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

SE REFIERE A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE A LA INTEGRINA a5 1 Y COMPRENDE: A) UNA REGION DE LA CADENA PESADA VARIABLE (VH) SELECCIONADA DE LA SECUENCIA DE AMINOACIDOS SEQ ID Nº: 1, SEQ ID Nº: 3, SEQ ID Nº: 5, ENTRE OTROS; B) UNA REGION DE LA CADENA LIGERA VARIABLE (VL) SELECCIONADA DE LA SECUENCIA DE AMINOACIDOS SEQ ID Nº: 2, SEQ ID Nº: 4, SEQ ID Nº: 6, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO Y UN AGENTE QUIMIOTERAPEUTICO. DICHO ANTICUERPO ES UNA INMUNOGLOBULINA G (IgG) SIENDO UTIL EN EL TRATAMIENTO DE CANCER
PE2007000634A 2006-05-24 2007-05-23 ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA PE20080100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
PE20080100A1 true PE20080100A1 (es) 2008-04-18

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000634A PE20080100A1 (es) 2006-05-24 2007-05-23 ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA

Country Status (23)

Country Link
US (1) US20090081207A1 (es)
EP (1) EP2032605A2 (es)
JP (1) JP2009537158A (es)
KR (1) KR20090027218A (es)
CN (1) CN101495515A (es)
AR (1) AR061107A1 (es)
AU (1) AU2007253586A1 (es)
BR (1) BRPI0711796A2 (es)
CA (1) CA2652886A1 (es)
CL (1) CL2007001488A1 (es)
CR (1) CR10456A (es)
DO (2) DOP20070101A (es)
EA (1) EA200802348A1 (es)
EC (1) ECSP088909A (es)
MA (1) MA30425B1 (es)
MX (1) MX2008014910A (es)
NO (1) NO20085362L (es)
PE (1) PE20080100A1 (es)
TN (1) TNSN08469A1 (es)
TW (1) TW200817433A (es)
UY (1) UY30362A1 (es)
WO (1) WO2007134876A2 (es)
ZA (1) ZA200810850B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1961065A4 (en) 2005-10-31 2009-11-11 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
NZ598594A (en) 2006-03-21 2014-01-31 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2009042746A1 (en) 2007-09-26 2009-04-02 Genentech, Inc. Novel antibodies
KR20100115360A (ko) * 2008-02-05 2010-10-27 브리스톨-마이어스 스큅 컴퍼니 알파 ５-베타 １ 항체 및 이의 용도
TWI506037B (zh) * 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
WO2010054212A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
SG10201609416XA (en) * 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
PL2933262T3 (pl) * 2010-07-09 2018-10-31 Affibody Ab Polipeptydy
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CN104302650B (zh) 2012-03-13 2017-07-18 瑞斯比维特有限公司 晶体pi3激酶抑制剂
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
KR102390445B1 (ko) * 2012-12-26 2022-04-25 온코시너지, 인코포레이티드 항-인테그린 β1 항체 조성물 및 이의 이용 방법
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN108430489B (zh) 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
EP3916014A4 (en) * 2019-07-24 2022-10-26 Korea Basic Science Institute SINGLE DOMAIN ANTIBODIES TARGETED AGAINST AVSS3 INTEGRIN
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
AU2003298783B2 (en) * 2002-11-26 2010-11-04 Abbvie Biotherapeutics Inc. Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7662384B2 (en) * 2004-03-24 2010-02-16 Facet Biotech Corporation Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
NZ598594A (en) * 2006-03-21 2014-01-31 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists

Also Published As

Publication number Publication date
EP2032605A2 (en) 2009-03-11
WO2007134876A2 (en) 2007-11-29
CA2652886A1 (en) 2007-11-29
ECSP088909A (es) 2008-12-30
MX2008014910A (es) 2009-01-23
KR20090027218A (ko) 2009-03-16
ZA200810850B (en) 2010-05-26
US20090081207A1 (en) 2009-03-26
WO2007134876A8 (en) 2009-07-02
TW200817433A (en) 2008-04-16
EA200802348A1 (ru) 2009-08-28
JP2009537158A (ja) 2009-10-29
CL2007001488A1 (es) 2008-01-04
DOP2007000101A (es) 2007-12-31
AU2007253586A1 (en) 2007-11-29
AR061107A1 (es) 2008-08-06
DOP20070101A (es) 2007-12-30
UY30362A1 (es) 2008-01-02
CR10456A (es) 2009-02-26
NO20085362L (no) 2009-02-23
BRPI0711796A2 (pt) 2011-12-06
CN101495515A (zh) 2009-07-29
WO2007134876A3 (en) 2008-03-27
MA30425B1 (fr) 2009-05-04
TNSN08469A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
PE20080100A1 (es) ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20120014A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9
ES2567402T3 (es) Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
MX2024004322A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
CR6425A (es) Anticuerpos monoclonales humanos de ctla-4
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
TW200732350A (en) Methods for generating monovalent IgG
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
WO2005016969A3 (en) Cd20-binding polypeptide compositions
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PE20081899A1 (es) Anticuerpos anti-ige
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
PE20061043A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
PE20110774A1 (es) Anticuerpos para ccr2
PE20110797A1 (es) Anticuerpos anti mn
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes

Legal Events

Date Code Title Description
FD Application declared void or lapsed